| STOP-214 (1999) | 76 | 5 | 194/98 | ∼158/80 in both groups | Beta blocker or thiazide (older drugs) vs. ACE inhibitor or calcium channel blocker (newer drugs) | Regimens did not differ in rates of stroke, cardiovascular events, or mortality. |
| | | | | | ACE inhibitor better than calcium channel blocker for myocardial infarction (NNT = 26) and congestive heart failure (NNT = 28). |
| LIFE15 (2002) | 70 | 4 | 174/98 | ∼145/81 in both groups | ARB (losartan) vs. beta blocker (atenolol) | ARB better than beta blocker for stroke (NNT = 50) and combined end point of cardiovascular mortality, stroke, and myocardial infarction (NNT = 50). |
| | | | | | Regimens did not differ in rates of total mortality. |
| ALLHAT13 (2002) | 67 | 5 | 146/84 | ∼134/85 in all groups | Thiazide (chlorthalidone) vs. ACE inhibitor (lisinopril) vs. calcium channel blocker (amlodipine) | Regimens did not differ in combined end point of fatal coronary heart disease or nonfatal myocardial infarction. |
| | | | | | Thiazide better than calcium channel blocker for congestive heart failure (NNT = 40) and angina (NNT = 67). |
| | | | | | Thiazide better than ACE inhibitor for stroke (NNT = 111), cardiovascular disease (NNT = 77), congestive heart failure (NNT = 100), or revascularization (NNT = 100). |
| | | | | | Regimens did not differ in rates of total mortality. |
| INVEST16 (2003) | 66 | 2 | 150/87 | ∼131/77 in both groups | Calcium channel blocker (verapamil) plus ACE inhibitor (trandolapril) vs. beta blocker (atenolol) plus thiazide (hydrochlorothiazide) | Regimens did not differ in rates of cardiovascular outcomes or total mortality. |
| ANBP217 (2003) | 72 | 4 | 168/91 | ∼142/79 in both groups | ACE inhibitor (enalapril) vs. thiazide (hydrochlorothiazide) | ACE inhibitor better than thiazide for primary end point of all cardiovascular events or total mortality (NNT = 72) and for myocardial infarction (NNT = 125). |
| | | | | | Regimens did not differ in rates of total mortality. |